(Press-News.org) Men over 60 with low-risk prostate cancer could spend ten years with no active treatment, have a better sex life as a result, yet still be very unlikely to die from the disease, new research has found.
The findings come from two new studies looking at 'active surveillance' of prostate cancer - when the disease is closely monitored but not treated - presented at the European Association of Urology congress, EAU21, today.
The first uses data from Sweden's National Prostate Cancer Register, which has information on virtually every man diagnosed with the disease in that country since 1998 - 23,649 of whom went on active surveillance.
Active surveillance was introduced between 15 and 20 years ago for men with low-risk prostate cancer, so as yet, there is no data on the risks and benefits over a longer time period. The researchers, from Uppsala University and the University of Gothenburg, devised a new statistical technique to fill this gap.
Rather than looking simply at the numbers of patients on active surveillance who died of prostate cancer, they identified how many moved on from active surveillance to other treatments, such as radiotherapy or surgery. As these treatments have been provided for many years, long-term follow up data on them already exists.
This allowed the researchers to model the likely outcomes for men on active surveillance up to 30 years from diagnosis, based on the numbers moving onto different treatments. They were able to show not only the percentage of men who would die from the disease over that period, but also the number of years they would spend without treatment, post diagnosis.
Eugenio Ventimiglia, a urologist at San Raffaele Hospital in Milan (Italy) and a PhD student at the Department of Surgical Sciences, Uppsala University (Sweden) explained: "We wanted to identify the real winners from active surveillance, the men who are unlikely to die from their prostate cancer but who will also spend most of their remaining years without treatment if the disease is carefully monitored.
"Obviously, the older you are and the lower risk your cancer, the greater the benefit. But we saw a real divide at age 60. Men diagnosed under 60 on active surveillance have a greater likelihood of dying of prostate cancer with very little added benefit, in terms of extra years with no other treatment. After sixty, if your cancer is low-risk, then active surveillance is really a win-win: the model showed men having ten years or more without other treatment with only a low percentage likely to die from the disease."
Low impact on sexual function
Other treatments for prostate cancer - such as radiotherapy or surgery - can result in incontinence and erectile dysfunction, whereas the physical side effects of active surveillance are minimal. Other research being presented at EAU21 today found that men on active surveillance report fewer problems with sexual function than those on other treatments.
The research draws on data from the EUPROMS study (Europa Uomo Patient Reported Outcome Study), the first prostate cancer quality of life survey conducted by patients for patients. Just under 3,000 men from 24 European countries diagnosed with prostate cancer have completed the survey at home in their own time. This allows them more time to consider their answers and report how they really feel, compared to questionnaires carried out in a clinical environment.
The survey showed that under 45 percent of men on active surveillance reported problems having an erection, compared to between 70 and 90 percent of men on other treatments.
Lionne Venderbos, Postdoctoral Researcher at Erasmus MC, Rotterdam, who analysed the survey results said: "Lack of sexual function affects patients' quality of life more than any other reported side effect. The survey shows that active surveillance has the least impact on sexual function of all possible treatment options.
"This is important for men diagnosed with prostate cancer to be aware of, before they decide which treatment option to pursue. Men who choose active surveillance as their preferred option have the same survival rates over five years as those who chose surgery or radiation, but can also maintain sexual function."
Hendrik Van Poppel, Emeritus Professor of Urology at Katholieke Universiteit Leuven, Belgium, and member of the EAU Executive, said: "When men diagnosed with prostate cancer are deciding their treatment option, quality of life is often the most important factor. As these studies show, active surveillance has the least negative impact, but that treatment option is only possible when the disease is diagnosed at an early stage. It's vital to pick up this disease early, and the option of active surveillance should encourage men to overcome their reluctance to be tested for prostate cancer. Prostate cancer can be fatal, but also the later the diagnosis, the more severe the treatments and the greater the impact on quality of life."
INFORMATION:
Care homes need to be vigilant for outbreaks of COVID-19, even after residents have received two doses of the vaccine, according to new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
Long-term care facilities, such as care homes with elderly residents with multiple underlying conditions, are at high risk of COVID-19 outbreaks and many vaccination campaigns have initially focused on care home residents and the staff looking after them. An outbreak in a French care home, however, raises questions about how effective the vaccine is in the elderly.
Martin Martinot, of ...
COVID-19 outbreaks in French nursing homes almost certainly started in staff - and none of measures put in place stopped the virus from taking hold, new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, shows.
Residents of long-term care facilities represent a small fraction of the general population but account for a disproportionate number of SARS-CoV-2-related deaths in many countries.
In France, 5,203 outbreaks (of 1 case or more) were reported in nursing homes during the first wave of COVID-19. In the Auvergne-Rhône-Alpes region, there were 651 outbreaks, 3,885 residents had confirmed COVID-19 infection and 1,772 ...
The flu vaccine may provide vital protection against COVID-19, new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held online this year, concludes.
An analysis of patient data from around the world strongly suggests that the annual flu shot reduces the risk of stroke, sepsis and DVT in patients with COVID-19. Patients with COVID-19 who had been vaccinated against flu were also less likely to visit the emergency department and be admitted to the intensive care unit (ICU).
Immunising the world against COVID-19 is a daunting challenge and, although production and distribution of vaccines increases daily, some countries are not expected to vaccinate large numbers of their population ...
A vaccine to protect against infection with hepatitis C could be in use within 5 years, says Professor Sir Michael Houghton, who won the Nobel Prize for Medicine and Physiology along with three other scientists for discovering the hepatitis C virus (HCV) in 1989. Sir Michael will discuss the development of a vaccine in a special presentation at this year's European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held online this year.
Up to 2 million new HCV infections occur every year around the world, with an estimated 70 million carriers of the virus globally, most of whom are not diagnosed. The virus is estimated to cause some 400,000 deaths annually. Many infected with the virus go on to develop liver cirrhosis and liver cancer.
"While the advent of ...
Water-jet nozzles in electric toilets--commonly used in Japan and other parts of Asia--may be reservoirs for multidrug-resistant Pseudomonas aeruginosa (MDRP) in hospitals, increasing the risk of dangerous germ transmission among patients, according to new research being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) held online this year.
"This is the first report of hospital transmissions associated with electric toilets and could have major implications for infection control," says Dr Itaru Nakamura from Tokyo Medical University Hospital ...
New research presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) taking place online (9-12 July) shows that covering high-touch (the most regularly touched) surfaces in hospitals with silver-impregnated foil could significantly reduce levels of contamination by clinically important bacterial pathogens.
The study by Professor Andreas Widmer and colleagues at the University Hospital Basel, Basel, Switzerland, evaluated the antimicrobial effectiveness of a polyvinyl chloride (PVC) foil containing an integrated silver-based agent containing 2% silver ions.
The hospital environment has increasingly been recognised as having critical importance when formulating infection control measures ...
Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found.
The study, presented today at the European Association of Urology congress, EAU21, followed more than 1500 patients over three years. Patients classed as obese - with a BMI over 30 - had a ten percent higher survival rate than thinner patients over 36 months.
Although obesity is usually associated with an increased risk of death from many cancers and some other chronic diseases, there is some evidence in a few cancers of a survival advantage for patients with high body mass index. ...
Being immersed in a stunning 'virtual' Icelandic landscape can reduce the pain caused by uncomfortable medical procedures, new research has found.
The study compared patients with and without virtual reality (VR) headsets having rigid cystoscopies, where a rigid telescope is inserted through the urethra into the bladder. The research is being presented today at the European Association of Urology congress, EAU21.
Diagnosing and treating bladder cancer usually requires checking the bladder through a cystoscopy, which is perceived by patients as unpleasant and painful. Some patients avoid follow-up and as a result suffer uncontrolled and irreversible development of the disease. It is possible to have a flexible cystoscopy, which is less painful, ...
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment.
Professor Johann de Bono, Professor of Experimental Cancer Medicine at The ...
Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.
The findings from the Phase III trial are presented today at the European Association of Urology congress (EAU21).
There is a high risk of kidney cancer returning, following surgery to remove tumours, but there is currently no treatment to help prevent this.
The KEYNOTE study involved just under 1000 patients with kidney cancer who had undergone surgery. Half of them were given the immunotherapy drug pembrolizumab, or pembro, and the other half a placebo.
Pembro is used to treat a number of cancers, including late-stage kidney cancer, where the disease has spread to ...
